| Mackenzie Farmer, OTR/L | |
|
654 Highland Ave Ste 17, Fort Thomas, KY 41075-1762 | |
| (859) 441-0139 | |
| Not Available |
| Full Name | Mackenzie Farmer |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 654 Highland Ave Ste 17, Fort Thomas, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124698188 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mackenzie Farmer, OTR/L 6802 Whitehall Ave, Cincinnati, OH 45230-2925 Ph: () - | Mackenzie Farmer, OTR/L 654 Highland Ave Ste 17, Fort Thomas, KY 41075-1762 Ph: (859) 441-0139 |
News Archive
Researchers at Seattle Children's Research Institute and their collaborators have discovered a pair of defective genes that cause a rare congenital malformation syndrome that can make it impossible for the child to breathe or eat properly without reparative surgery.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Towers Watson, a global professional services company, announced today that it has signed an agreement to acquire Extend Health, Inc., which operates the largest private Medicare exchange in the United States.
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
› Verified 8 days ago
Marissa Nicole Visse, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 100 Carmel Manor Dr, Fort Thomas, KY 41075 Phone: 859-781-5111 | |
Miss Mindy Lynn Ortlieb, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 85 N Grand Ave, Fort Thomas, KY 41075 Phone: 859-572-3120 | |
Kristin Mardis, MSOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Carmel Manor Dr, Fort Thomas, KY 41075 Phone: 859-781-5111 | |
Mrs. Valerie P Miller, M.S. OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 50 Southview Ave, Fort Thomas, KY 41075 Phone: 859-653-1762 | |
Courtney Schott, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Carmel Manor Dr, Fort Thomas, KY 41075 Phone: 419-206-7213 | |
Meredith Joan Klare, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 18 N Fort Thomas Ave Ste 302, Fort Thomas, KY 41075 Phone: 859-441-0139 |